Online inquiry

IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ14704MR)

This product GTTS-WQ14704MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Sickle Cell Disease (SCD) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 1
Species	Humanized
RefSeq	NM_003005.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	6403
UniProt ID	P16109

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14704MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ8244MR	IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	HLX10
GTTS-WQ11192MR	IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	MEDI0562
GTTS-WQ13064MR	IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	PEG-IFN-SA
GTTS-WQ5974MR	IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	CLLB8
GTTS-WQ5418MR	IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	CD74-DOX (ADC)
GTTS-WQ9067MR	IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	IMC-A12
GTTS-WQ2729MR	IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	AMG-139
GTTS-WQ8540MR	IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	Hu5A8

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST